Brief: Altimmune Announces Positive Topline Results From The Impact Phase 2B Trial Of Pemvidutide
26/06/2025 12:04
June 26 (Reuters) - Altimmune Inc ALT.O: ALTIMMUNE ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE IMPACT PHASE 2B TRIAL OF PEMVIDUTIDE IN THE TREATMENT OF MASH ALTIMMUNE INC - TRIAL ACHIEVES 59.1% MASH RESOLUTION WITHOUT WORSENING FIBROSIS ALTIMMUNE INC: TRIAL MET ITS PRIMARY ENDPOINT ALTIMMUNE INC - WEIGHT LOSS OF UP TO 6.2% AT 24 WEEKS IN TRIAL Source text: ID:nGNXp967x Further company coverage: ALT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Altimmune
See all newsFactbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Boehringer-Zealand's obesity drug shows promise in cutting visceral, liver fat
U.S. RESEARCH ROUNDUP-Costco Wholesale, HCA Healthcare, Micron Technology
Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial (updated)